MMP1 and synovial sarcoma: Pretreatment with myricetin and its effects on decreased the up-regulation of matrix metalloproteinase 1 (MMP-1) and IL-6, as well as inhibiting the phosphorylation of p38 and JNK in human synovial sarcoma cells in vitro [65].